Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Enterprise Value: 2019-2025

Historic Enterprise Value for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to $3.5 billion.

  • Kymera Therapeutics' Enterprise Value rose 45.11% to $3.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 62.14%. This contributed to the annual value of $1.5 billion for FY2024, which is 29.71% down from last year.
  • As of Q3 2025, Kymera Therapeutics' Enterprise Value stood at $3.5 billion, which was up 62.71% from $2.2 billion recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Enterprise Value ranged from a high of $3.5 billion in Q3 2025 and a low of $312.5 million during Q3 2023.
  • Its 3-year average for Enterprise Value is $1.7 billion, with a median of $1.7 billion in 2024.
  • In the last 5 years, Kymera Therapeutics' Enterprise Value surged by 3,092.98% in 2021 and then crashed by 73.71% in 2022.
  • Quarterly analysis of 5 years shows Kymera Therapeutics' Enterprise Value stood at $2.8 billion in 2021, then tumbled by 49.55% to $1.4 billion in 2022, then soared by 47.57% to $2.1 billion in 2023, then fell by 29.71% to $1.5 billion in 2024, then surged by 45.11% to $3.5 billion in 2025.
  • Its Enterprise Value stands at $3.5 billion for Q3 2025, versus $2.2 billion for Q2 2025 and $1.2 billion for Q1 2025.